OncRef

Clinical Trial: NCT04026412

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Bristol-Myers Squibb
Information Provided By:Bristol-Myers Squibb
Last Update Posted:2025-07-24

Study Overview

Brief Summary

The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).

Official Title

A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Intervention / Treatment

  • Biological: nivolumab
  • Biological: ipilimumab
  • Biological: durvalumab

Other Study ID Numbers

  • CA209-73L
  • 2019-001222-98
  • 2019

Start Date (Actual)

2019-10-08

Primary Completion Date (Actual)

2024-03-22

Study Completion Date (Actual)

2024-11-26

Enrollment (Actual)

925

Study Type

Interventional

Phase

Phase 3